Clinical trials: Opioid-induced Constipation
Constipation, Opioid-Induced
Prevention of Opioid-induced Constipation in Patients With Advanced Cancer
More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids.
- Trial name
- OMAMA (NCT05216328)
- Testing
- Macrogol Only Product in Oral Dose Form, Magnesium hydroxide 724mg
- Where
- 13 sites in Netherlands
- Volunteers
- 258 people
- Sponsor
- Amsterdam UMC, location VUmc
Opioid-induced Constipation
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced…
- Trial name
- NCT03720613
- Testing
- Naldemedine, Lubiprostone, Naloxegol
- Where
- United States
- Volunteers
- 34,532 people
- Sponsor
- BioDelivery Sciences International
Opioid-Induced Constipation (OIC)
Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive…
- Trial name
- NCT05588323
- Testing
- Naldemedine
- Where
- 16 sites in Albania, Armenia and 6 more
- Volunteers
- 24 people
- Sponsor
- Shionogi
Opioid-Induced Nausea and Vomitting(OINV)
Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study
Opioid analgesics can cause side effects such as constipation, nausea, and vomiting by acting on opioid receptors widely distributed in the peripheral nervous system.
- Trial name
- NCT07038551
- Testing
- Naldemedine
- Where
- 20 sites in Japan
- Volunteers
- 120 people
- Sponsor
- International University of Health and Welfare
Healthy, Opioid-induced Constipation
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).
- Trial name
- NCT01040637
- Testing
- TD-1211
- Where
- 3 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Opioid-induced Constipation (OIC)
A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.
- Trial name
- NCT01333540
- Testing
- TD-1211
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Glycyx Therapeutics
Opioid Induced Constipation
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
- Trial name
- NCT01401985
- Testing
- TD-1211
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Glycyx Therapeutics
Opioid Induced Constipation
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation
- Trial name
- NCT01459926
- Testing
- TD-1211
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- Glycyx Therapeutics
Constipation
TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects
The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.
- Trial name
- NCT01655771
- Testing
- TD-1211 Dose 1, TD-1211 Dose 2
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
OIC
TD-1211 IV/Oral Mass Balance Study
The purpose of this study is to determine TD-1211 is processed by the body.
- Trial name
- NCT01702194
- Testing
- TD-1211 IV [C14], TD-1211 PO [C14]
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Postoperative Ileus (Post Cardiac Surgery Constipation)
Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery
Postoperative ileus, defined as the transient postoperative functional inhibition of propulsive bowel activity, commonly occurs in patients after cardiac surgery and contributes to postoperative morbidity.
- Trial name
- TRANSIT (NCT04433390)
- Testing
- Naloxegol, inert tablet
- Where
- France
- Volunteers
- 305 people
- Sponsor
- CMC Ambroise Paré
Cancer, Opioid Induced Constipation (OIC)
Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience
This study looks at how well a medicine called naldemedine works for people with cancer who become constipated while taking opioids. Opioids are medications prescribed to treat persistent or severe pain.
- Trial name
- NOCON (NCT07231796)
- Testing
- Naldemedine, an peripherally acting opioid antagonist
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Professor Monique A. H. Steegers
Constipation, Opioid-Induced, Cancer
Electroacupuncture for Opioid-Induced Constipation in Cancer Patients: A Randomized Clinical Trial
The primary objective of this trial is to evaluate the efficacy and safety of electroacupuncture in the management of opioid-induced constipation in patients with cancer.
- Trial name
- NCT06537440
- Testing
- Electroacupuncture
- Where
- China
- Volunteers
- 92 people
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Constipation, Opioid-Induced
Fiber-Enriched Enteral Nutrition and Opioid-Induced Constipation in the ICU
Opioid use for sedation and analgesia is widespread among mechanically ventilated ICU patients, often leading to gastrointestinal dysfunction and opioid-induced constipation (OIC).
- Trial name
- NCT07201428
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Opioid-induced Constipation in Patients With Cancer
Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer
Approximately 70-80% of patients with advanced disease will be affected by moderate to severe pain. Opioid analgesics represented by morphine and oxycodone are the cornerstone of cancer-pain management, and recommended for use in…
- Trial name
- NCT03797586
- Testing
- Electroacupuncture group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Opioid-Induced Constipation
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
The purpose of this study is to assess safety and preliminary efficacy of BGP345A in patients with constipation due to the use of opioid-based medications for the management of chronic non cancer pain.
- Trial name
- OIC1 (NCT05133076)
- Testing
- Lactobacillus gasseri BGP345A
- Where
- 4 sites in France
- Volunteers
- 14 people
- Sponsor
- BioGaia Pharma AB
Opioid-Induced Constipation
European Study of Opioid Induced Constipation
Constipation is common (40-90%) in advanced cancer patients , and has a significant negative impact on quality of life. The aetiology of constipation is often multifactorial in advanced cancer patients.
- Trial name
- E-StOIC (NCT05149833)
- Where
- Ireland
- Volunteers
- 1,200 people
- Sponsor
- University of Dublin, Trinity College
Opioid-Induced Constipation, Pain Cancer
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.
- Trial name
- NCT06897917
- Testing
- Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Henan Cancer Hospital
Opioid Induced Constipation
Naloxegol Drug Utilization Post Authorisation Safety Study
This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway…
- Trial name
- NCT02813148
- Testing
- Naloxegol
- Where
- 4 sites in Germany, Norway and 2 more
- Volunteers
- 17,254 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Opioid Induced Constipation
Naloxegol Health Outcome Post Authorisation Safety Study
This post-authorization observational safety study (PASS) monitors clinically important identified and potential risks within a cohort of patients treated with naloxegol, including the occurrence of bowel perforation, acute…
- Trial name
- NCT02813369
- Testing
- naloxegol, non-PAMORA laxative
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd